Stryker Co. (NYSE:SYK) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Stryker Co. (NYSE:SYK - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $331.52.

Several equities analysts recently weighed in on the stock. Morgan Stanley raised their price objective on shares of Stryker from $300.00 to $320.00 and gave the company an "equal weight" rating in a research report on Monday, December 4th. Canaccord Genuity Group raised shares of Stryker from a "hold" rating to a "buy" rating and raised their price objective for the company from $315.00 to $360.00 in a research report on Wednesday, January 31st. Roth Mkm lifted their price target on shares of Stryker from $345.00 to $348.00 and gave the company a "buy" rating in a research report on Wednesday, January 31st. Royal Bank of Canada reissued an "outperform" rating and issued a $360.00 price target on shares of Stryker in a research report on Thursday, February 15th. Finally, Canaccord Genuity Group raised shares of Stryker from a "hold" rating to a "buy" rating and set a $360.00 price target on the stock in a research report on Wednesday, January 31st.

Insider Transactions at Stryker

In other Stryker news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now owns 14,242 shares in the company, valued at $4,856,522. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the sale, the director now owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now owns 14,242 shares in the company, valued at approximately $4,856,522. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 212,109 shares of company stock worth $72,845,768. Insiders own 5.90% of the company's stock.

Institutional Investors Weigh In On Stryker

Institutional investors and hedge funds have recently made changes to their positions in the company. Burkett Financial Services LLC acquired a new stake in shares of Stryker in the 4th quarter valued at $25,000. Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in shares of Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. Quarry LP acquired a new stake in shares of Stryker in the 1st quarter valued at $27,000. Rogco LP acquired a new stake in shares of Stryker in the 4th quarter valued at $30,000. Finally, Clear Street Markets LLC acquired a new stake in shares of Stryker in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Trading Down 0.2 %

Shares of SYK traded down $0.84 during midday trading on Friday, hitting $357.87. The stock had a trading volume of 1,074,753 shares, compared to its average volume of 1,130,776. The business has a 50-day simple moving average of $344.28 and a two-hundred day simple moving average of $305.97. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The firm has a market cap of $136.16 billion, a P/E ratio of 43.38, a price-to-earnings-growth ratio of 2.92 and a beta of 0.89. Stryker has a fifty-two week low of $249.98 and a fifty-two week high of $361.41.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.27 by $0.19. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm's revenue was up 11.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.00 earnings per share. As a group, equities analysts forecast that Stryker will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.89%. Stryker's payout ratio is 38.79%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.